09 nov
|
Alexion, AstraZeneca Rare Disease
|
Barcelona
09 nov
Alexion, AstraZeneca Rare Disease
Barcelona
Lead the development and commercialization strategy for rare bone and endocrine disorders, focusing on Hypophosphatasia. This role involves integral and local market collaboration, launch planning, and driving business performance within a matrix structure.
📌 Ai-Driven Coa Strategy Lead – Patient-Centric (Barcelona)
🏢 Alexion, AstraZeneca Rare Disease
📍 Barcelona